Efficacy of Bimekizumab and Other Biologics in Moderate to Severe Plaque Psoriasis: A Systematic Literature Review and a Network Meta-Analysis

INTRODUCTION: Biologic treatments are increasingly being used in the management of moderate to severe plaque psoriasis (PSO). Bimekizumab is a selective inhibitor of both interleukin (IL)-17A and IL-17F approved for the treatment of moderate to severe PSO. Although bimekizumab trials provide compari...

Descripción completa

Detalles Bibliográficos
Autores principales: Armstrong, April, Fahrbach, Kyle, Leonardi, Craig, Augustin, Matthias, Neupane, Binod, Kazmierska, Paulina, Betts, Marissa, Freitag, Andreas, Kiri, Sandeep, Taieb, Vanessa, Slim, Mahmoud, Gomez, Natalie Nunez, Warren, Richard B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9357587/
https://www.ncbi.nlm.nih.gov/pubmed/35798920
http://dx.doi.org/10.1007/s13555-022-00760-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9357587/
https://www.ncbi.nlm.nih.gov/pubmed/35798920
http://dx.doi.org/10.1007/s13555-022-00760-8

Ejemplares similares